hotspot -WSS

hotspot

author：comprehensive 2025-09-30 00:47:16 - browse：213

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Medicare slashes safety net hospital payments by nearly $1 billion

leisure time

WSS

FDA early review: GLP

Physician assistants need a new name. Here's what it should be

Does Paxlovid work in people vaccinated against Covid

FDA approves Sage Therapeutics’ rapid

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

explore

hotspot

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How I helped Pfizer think through the ethics of Viagra

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA approves Sage Therapeutics’ rapid

Peter Hotez and the public health issue of online harassment

FDA scientists endorse Pfizer/BioNTech Covid

Affirmative action in medical school literally saved lives

How I helped Pfizer think through the ethics of Viagra

Sports medicine is finally prioritizing gender equality

Medicare Advantage overpayments discussion gets experts fired up

leisure time

FDA scientists endorse Pfizer/BioNTech Covid

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Gene therapy denied for Afghan refugee whose father aided U.S.

Heart disease in astronauts blamed on cosmic radiation

Merck to acquire Harpoon Therapeutics for $680 million

CDC recommends RSV monoclonal antibody for infants

explore

hotspot

leisure time

focus